Otsuka terminates development of treatment for agitation due to Alzheimer’s disease
Add topic to email alerts Subscribe We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Otsuka Pharmaceutical has terminated its development of AVP- …